According to recent reports, the drug quality regulator in India is to ask companies carrying the drug rosiglitazone to add a serious warning to the packaging that makes patients and healthcare professionals aware of the potential risks to heart patients.
The American Diabetes Association and European Association for the study of Diabetes have both removed rosiglitazone from their lists of recommended drugs. The move has prompted the Drug Controller General of India to make the change.
A DCGI controller reportedly commented: "Rosiglitazone is under continuous focus of our pharmacovigilance expert committee. We are monitoring the drug. We have asked all manufacturers to print a warning on the label of all formulations containing rosiglitazone to caution heart patients against using the drug."
As many as 30 different pharmaceutical companies in India currently market generic versions of the drug, as well as the inventor GlaxoSmithKline. The drug has faced falling sales following controversy in the last two years.
Diabetes drug will include warning
Thu, 04 Dec 2008
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.
Also related to this storyDiabetes newsletter
Diabetes based financial services
Call for diabetics to help each other
Using the internet to fight diabetes
New Zealanders get a diabetes warning
Glaxo little affected by diabetes drug warning
Strictest health warning on diabetes drugs
Diabetes blood glucose meters warning
The warning signs of diabetes in children
Hope in early warning for diabetes
Diabetes Warning for Obese Children
Warnings for diabetes drugs
Doomsday warning of diabetes wiping out Maori were overblown
Further warning for diabetes drug box
Diabetes drug will include new warning
Stiff FDA warning from Avandia
Byetta diabetes drug subject to warnings
Erectile dysfunction early diabetes and heart disease warning
Warning over diabetes drug causes uncertainty
Warning about diabetes in Asia
What to do in light of diabetes drug warning
Charity warning for type 2 diabetes patients